Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allergy TherapeuticsLSE:AGY +8.82% PS Ratio is 6.73 as of Jul. 15, 2026, which is 233% above its 10-year median of 2.02. The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Allergy Therapeutics ranks worse than 78.01% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Allergy Therapeutics's share price is £0.074.
Allergy Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was £0.01. Hence, Allergy Therapeutics's PS Ratio for today is 6.73.
Good Sign:
Allergy Therapeutics PLC stock PS Ratio (=5.6) is close to 1-year low of 5.5.
The historical rank and industry rank for Allergy Therapeutics's PS Ratio or its related term are showing as below:
LSE:AGY'
s PS Ratio Range Over the Past 10 Years
Min: 0.09 Med: 2.02 Max: 10.08
Current: 6.8
During the past 13 years, Allergy Therapeutics's highest PS Ratio was 10.08. The lowest was 0.09. And the median was 2.02.
LSE:AGY's PS Ratio is ranked worse than 78.01% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs LSE:AGY: 6.80
Allergy Therapeutics PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Allergy Therapeutics was -8.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -52.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -40.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -14.50% per year.
During the past 13 years, Allergy Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 14.40% per year. The lowest was -52.60% per year. And the median was 0.90% per year.
Back to Basics: PS Ratio
Allergy Therapeutics (LSE:AGY) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Allergy Therapeutics PS Ratio Related Terms
Allergy Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Allergy Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allergy Therapeutics PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Allergy Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Allergy Therapeutics's Share Price of today is £0.074.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Allergy Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was £0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Allergy Therapeutics (LSE:AGY) has a PS Ratio of 6.73 as of Jul. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Allergy Therapeutics and its competitors. This is 233% above median its historical median of 2.02. Over the past decade, Allergy Therapeutics' PS Ratio has ranged from 0.09 to 10.08. According to the industry distribution chart, Allergy Therapeutics ranks #745 out of 955 companies in the Drug Manufacturers industry, placing it in the top 78%.
Is Allergy Therapeutics' PS Ratio too high?
Allergy Therapeutics' current PS Ratio of 6.73 is 233% above median its 10-year median of 2.02. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 10.08. The Drug Manufacturers industry median PS Ratio is 2.33. Allergy Therapeutics' value of 6.73 is 188.8% above this industry median. Based on the distribution chart, Allergy Therapeutics ranks #745 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Allergy Therapeutics' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #745 out of 955 companies for PS Ratio. This places Allergy Therapeutics in the lower half of its industry. The industry median PS Ratio is 2.33. Allergy Therapeutics' value of 6.73 is 188.8% above this benchmark. Historically, Allergy Therapeutics' own PS Ratio has ranged from 0.09 to 10.08 over the past decade. While the company's 10-year median is 2.02 vs. the industry median of 2.33, Allergy Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allergy Therapeutics's current PS Ratio of 6.73 is 188.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Allergy Therapeutics and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allergy Therapeutics's current PS Ratio is 6.73, which is 233% above median its own 10-year median of 2.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.07 — trading 146.7% above its estimated fair value. The current PS Ratio is 6.73, which is 233% above median its 10-year median of 2.02 and 188.8% above the Drug Manufacturers industry median of 2.33. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current PS Ratio is 6.73 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AGY has been successfully added to your 
